Issue Date: September 27, 2010
What a difference an amino acid makes. Five years ago, researchers noticed that many patients with rare blood cancers called myeloproliferative neoplasms, or MPNs, had a phenylalanine in place of a valine residue at a specific position on JAK2, a protein kinase involved in blood cell development. The discovery set off a hunt for molecules that could block the errant enzyme and thereby quash the diseases.
Today, a handful of JAK2 inhibitors have reached early . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society